Democrats push warning on insider prediction bets
Dozens of Democrats urged US regulators to warn federal employees against insider trading on prediction markets following reports of suspicious bets tied to government actions.

Finance journalist at Grafa. Covers tech, crypto, and markets, making complex finance clear for all. Passionate about innovation and trends.
Dozens of Democrats urged US regulators to warn federal employees against insider trading on prediction markets following reports of suspicious bets tied to government actions.
Australia is set to intensify its trade diplomacy as Trade Minister Don Farrell confirms a new round of high-level negotiations with India scheduled for the coming weeks.
Sigma Lithium (NASDAQ:SGML), a global producer of high-purity "Green Lithium" concentrate, today announced its financial and operational results for the fourth quarter of 2025 and the beginning of 2026.
AUD and NZD hit multi-month lows as Middle East conflict fears drive a flight to the US dollar.
Alkane Resources (ASX:ALK) has bolstered its financial position by executing a combined $150 million in new debt facilities.
The Star Entertainment Group (ASX:SGR) announced a binding commitment letter with WhiteHawk Capital Partners for a comprehensive debt refinancing package.
Kenon Holdings (NYSE:KEN), a holding company with interests in energy and shipping, reported its consolidated financial results for the full year 2025, driven largely by performance at its OPC Energy subsidiary.
Biogen (NASDAQ:BIIB) said the FDA approved a higher-dose regimen of its SPINRAZA (nusinersen) therapy for patients with spinal muscular atrophy (SMA).
Soluna Holdings (NASDAQ:SLNH), a specialized developer of green data centers for intensive computing applications such as Bitcoin mining and artificial intelligence, today announced its financial results for the fourth quarter and full year ended December 31, 2025.
United Therapeutics (NASDAQ:UTHR), a public benefit corporation, today announced that its pivotal TETON-1 study evaluating nebulized Tyvaso® (treprostinil) for the treatment of idiopathic pulmonary fibrosis (IPF) met its primary efficacy endpoint.